Reza Shojaei: On The 2nd Day of IPAW 2025, Let’s Focus on Patients, The Real Reason Plasma Matters!
Reza Shojaei, Chief Operating Officer at Canadian Plasma Resources, shared on LinkedIn:
”On the second day of IPAW 2025, let’s focus on patients, the real reason plasma matters.
Plasma-derived medicines treat life-threatening conditions such as primary immune deficiencies, hemophilia, and hereditary angioedema.
For many, these therapies are not optional; they are the only available treatment, turning what used to be fatal diseases into manageable conditions.
Every donation ensures someone, somewhere, gets another chance at health, at family life, at simply living fully.
Behind each unit of plasma is a powerful chain: a donor’s generosity, a patient’s survival, and then a family’s hope.
Let’s use this week to amplify the voices of patients and remind the world that plasma saves lives every single day.
If you know someone whose life has been touched by plasma therapies, share their story on social media, because awareness grows stronger when it’s personal.”

Stay updated on emerging topics in transfusion medicine with Hemostasis Today.
-
Dec 15, 2025, 15:58Khaled Musallam Applauds Hatoon Ezzat’s Leadership and Healthcare Advances in Saudi Arabia
-
Dec 15, 2025, 12:46Deborah Ebert Long on Hemophilia Care: Progress, Possibility, and the Power of Listening
-
Dec 15, 2025, 12:34Nathan Connell on Conversion from Eptacog Alfa to Beta
-
Dec 15, 2025, 12:17Danny Hsu on Interdisciplinary Toolkit for Gynecologic Bleeding on Anticoagulation
-
Dec 15, 2025, 12:08Ted Roh: A Historic Milestone for Indonesia’s Health Innovation
-
Dec 15, 2025, 11:28Wolfgang Miesbach Shares Insights from Davide Matino’s Presentation on Marstacimab at ASH25
-
Dec 15, 2025, 11:12Tushar Pandey Awarded for His Enourmous Contribution to Hematology
-
Dec 15, 2025, 11:07DISTRO: Vidya Rajbhoj on AI and Digital Technology to Improve Stroke Rehabilitation
-
Dec 15, 2025, 11:00Ischemic Stroke, AF and Atherosclerotis: Amira Khater on Sufficiency of Anticoagulant Monotherapy
